Urine Tests in Diagnosing Monoclonal Gammopathies
Author Information
Author(s): Mònica Vidal-Pla, Elisa Nuez-Zaragoza, Indira Bhambi, Vicente Aguadero
Primary Institution: Hospital Parc Taulí University, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, España
Hypothesis
When a patient has a low concentration of monoclonal component in serum, the probability of finding it in urine is also low.
Conclusion
Using specific cutoff points for serum monoclonal component concentration can reduce unnecessary urine tests, saving resources.
Supporting Evidence
- Patients with serum monoclonal component concentration ≤3.5 g/L and eGFR >30 mL/min/1.73m2 have a minimal chance of finding monoclonal component in urine.
- The study identified cutoff points that could prevent unnecessary urine tests in a significant number of cases.
- Using these cutoff points could optimize the use of analytical and healthcare resources.
Takeaway
If doctors find low levels of a certain protein in the blood, they might not need to check the urine, which can save time and effort.
Methodology
A retrospective study analyzed data from 132 patients with recent detection of monoclonal component in serum, comparing those with and without monoclonal component in urine.
Limitations
The study was conducted on a specific group of patients, and further research is needed to validate the findings in other populations.
Participant Demographics
Patients with recent detection of monoclonal component in serum, excluding those with biclonal paraproteins and light chain paraproteins.
Statistical Information
P-Value
<0.001
Confidence Interval
0.706–0.883
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website